Impact of highly active antiretroviral therapy in the treatment of HIV-infected patients with systemic non-Hodgkin's lymphoma

Acta Oncologica

Volumn 41, Issue 2, 2002, Pages 192-196

  Baiocchi, Otavio C G ^a   Colleoni, Gisele W B ^a   Navajas, Eduardo V ^a   Duarte, Luiz Claudio C ^a   Alves, Antonio C ^a   Andrade, Ana Lucia S S ^a   Kerbauy, Jose ^a   Oliveira, Jose Salvador R ^a  

^a Hematologia   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CELLS; CHEMOTHERAPY; PATIENT TREATMENT;

SURVIVAL CURVES;

ONCOLOGY;

ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; LAMIVUDINE; NELFINAVIR; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

ADULT; ANEMIA; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE STATUS; LYMPHOCYTE COUNT; MALE; NEUTROPENIA; NONHODGKIN LYMPHOMA; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; REMISSION; SIDE EFFECT; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV-1; HUMANS; LYMPHOMA, AIDS-RELATED; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PREDNISOLONE; RETROSPECTIVE STUDIES; SURVIVAL RATE; VINCRISTINE;

EID: 0036262483     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/028418602753669599     Document Type: Article

References (32)

1. Overview of the epidemiology of malignancy in immune deficiency
2. Cancer in children with primary or secondary immunodeficiencies
3. Overview of the epidemiology of immunodeficiency-associated cancers
4. Cancer incidence in a population with a high prevalence of infection with human immunodeficiency virus type 1
5. Effect of antiretroviral therapy on recent trends in selected cancers among HIV-infected persons
6. Non-Hodgkin's lymphoma among people with AIDS: Incidence, presentation and public health burden
7. Chemotherapy for HIV associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy (HAART) is not associated with excessive toxicity
8. The effects on survival of early treatment of human immunodeficiency virus infection
9. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
10. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 counts of 2000 per cubic milimeter or less
11. Trends in AIDS incidence, deaths, and prevalence - United States, 1996
12. The World Health Organization classification of hematological malignancies. Report of the clinical advisory committee meeting, Airlie House, Virginia
13. Report of the committee on Hodgkin's disease staging classification
14. A systematic overview of chemotherapy effects in aggressive non-Hodgkin's lymphoma
15. Antiretroviral therapy of human imunodeficiency virus infection
16. Report of an international workshop to standardize response criteria for Non-Hodgkin's lymphomas
17. Impact of combination therapy for HIV infection on inpatient census (letter)
18. Report of the NIH panel to define principles of therapy of HIV infection and guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents
19. Therapeutic approaches to HIV-associated non-Hodgkin's lymphoma
20. Age and serum lactate dehydrogenase level are independent prognostic factors in human immunodeficiency virus-related non-Hodgkin's lymphoma: A single-institute study of 96 patients
21. Prognostic factors in the treatment of HIV-associated non-Hodgkin's lymphoma. Analysis of AIDS Malignancy Clinical Group (ACTG) protocol 142: Low-dose vs. standard-dose m-BACOD + GM-CSF
22. Treatment of HIV-related non-Hodgkin's lymphoma adapted to prognostic factors
23. Weekly alternating combination chemotherapy for good prognosis AIDS-related lymphoma
24. Low-dose chemotherapy with central nervous system prophylaxis and zidovudine maintenance in AIDS-related lymphoma
25. Human immunodeficiency virus related lymphoma treated with intensive combination chemotherapy
26. Second-line chemotherapy in human immunodeficiency virus-associated non-Hodgkin's lymphoma
27. Prospective study with combined low-dose chemotherapy and zidovudine in 37 patients with poor prognosis AIDS-related non-Hodgkin's lymphoma
28. Clinical and virologic effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients receiving chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma: Results of a randomized trial
29. Low dose compared with standard dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodefficiency virus infection
30. Effect of highly active antiretroviral therapy (HAART) on response to therapy and survival in patients with AIDS-related non-Hodgkin's lymphoma treated with CHOP
31. Concomitant CHOP chemotherapy and HAART in patients with HIV-related non-Hodgkin's lymphoma
32. Changes in AIDS-related lymphoma (ARL) in the era of highly active antiretroviral therapy (HAART)